GlassScriptPhysician profile
Ashvin N Patel
NPI 1528129871
$4,055.23
in general payments reported to CMS, 2019-2025
20 companies · $495 in 2025
The $495 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $665 · 2020: $247 · 2021: $883 · 2022: $729 · 2023: $529 · 2024: $508 · 2025: $495.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,512 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,512.01 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $1,772.12 | 2019-2025 | Velphoro, Velphoro, Korsuva |
| Bayer Healthcare Pharmaceuticals INC. | $371.24 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $285.66 | 2021-2023 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $242.96 | 2021-2022 | |
| Glaxosmithkline, LLC. | $205.79 | 2021-2024 | Benlysta, Jesduvroq |
| Novo Nordisk INC | $205.00 | 2019-2022 | |
| Nxstage Medical, INC. | $132.44 | 2025 | Nxstage System One |
| Amgen INC. | $120.72 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.30 | 2019 | |
| Chiesi USA, INC. | $101.32 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $95.51 | 2020 | |
| Pfizer INC. | $86.50 | 2019 | |
| Novartis Pharmaceuticals Corporation | $83.13 | 2019 | |
| Mallinckrodt Hospital Products INC. | $76.65 | 2020-2021 | |
| Horizon Therapeutics Plc | $56.97 | 2023 | Krystexxa |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rockwell Medical, INC. | $31.36 | 2020 | |
| Neos Therapeutics, LP | $26.08 | 2020 | |
| Genentech USA, INC. | $20.16 | 2025 | Gazyva |
| Akebia Therapeutics INC | $20.00 | 2022 | |
| Ani Pharmaceuticals, INC. | $18.32 | 2024 | Purified Cortrophin Gel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashvin Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.